Liver Cancer News

Blue Faery: The Adrienne Wilson Liver Cancer Association



Liver Cancer News

Print Friendly, PDF & Email

Click on the title to read the rest of the Liver Cancer News story.

NICE Recommends Lenvima For Advanced Liver Cancer
21 December 2018
The National Institute for Health and Care Excellence (NICE) has recommended Lenvima (lenvatinib) for advanced Hepatocellular Carcinoma (HCC). The treatment will be available for people with advanced liver cancer, whose disease cannot be treated surgically. It works by slowing down the growth and spread of cancer cells by cutting off the blood supply that keeps cancer cells growing. Patients experienced a median overall survival of 13.6 months compared to 12.3 months with the alternative treatment Nexavar.

Oncimmune Signs Agreement With America’s Choice Provider Network To Expand Access To Its Blood Tests For The Early Detection Of Lung And Liver Cancers
20 December 2018
Oncimmune Holdings has entered into an agreement with America’s Choice Provider Network (ACPN) to expand access to simple and affordable blood tests, EarlyCDT®—Lung and EarlyCDT®—Liver. EarlyCDT—Liver aids in the detection and confirmation of Hepatocellular Carcinoma (HCC, liver cancer), in association with imaging, in high-risk patients with liver lesions of all sizes. Oncimmune technology detects evidence of the body’s natural response to cancer, enabling detection up to four years before standard clinical diagnosis. Oncimmune tests assist with clinical decision-making and are complementary to diagnostic technologies.

Association Between Aspirin Use And Risk Of Hepatocellular Carcinoma
17 December 2018
Researchers explored the associations between aspirin dose, duration of use, and the risk of developing Hepatocellular Carcinoma (HCC) nationwide. Their study included 87,507 men and 45,864 women who reported regular use aspirin tablets two or more times per week. Researchers found that these people had a 49% reduced risk of developing HCC. They then reviewed documentation of 108 incident HCC cases over 26 years, including 4,232,188 person-years. They observed reduced HCC risk in association with regular aspirin use vs nonregular use.

Liver Cancer Is The Most Common Cancer In Vietnam
13 December 2018
Liver cancer in Vietnam is rapidly increasing. In 2018, more than 25,000 Vietnamese people were diagnosed with liver cancer, and the mortality rate is high due to shortage of hepatitis B vaccination. For every 100,000 people, 23.2 have liver cancer, in both men and women. Professor Nguyen Chan Hung, head of the Vietnam Cancer Association, said in Vietnam, men are at risk for liver cancer three times higher than that of women. Hung also states that since is difficult to detect early the successful cure rate is unfortunately low.

Exelixis Initiates Pivotal Liver Cancer Study On Cabometyx
6 December 2018
Exelixis, Inc. is partnering with Ipsen to announce a pivotal phase III study called COSMIC-312. This study will evaluate Cabometyx (cabozantinib) in combination with Tecentriq to treat Hepatocellular Carcinoma (HCC). This combination treatment will be compared to Nexavar in previously untreated patients. The study will focus on progression-free survival, and overall survival results. In September, the Committee for Medicinal Products for Human had recommended the drug’s approval in Europe for a similar treatment.

Potential Markers Identified For Early Detection And Prevention Of Liver Cancer
5 December 2018
A recent study offers possible good news of early detection of Hepatocellular Carcinoma (HCC). The results of the study show a drastic increase in the expression of a sugar-burning enzyme called glycolytic enzymes. These enzymes are typically seen in pre-cancerous liver cells. This increase is associated with a higher risk of developing HCC. This increase could be used as a biomarker to identify people at risk of malignancy. Dr Salvatore Papa of the University of Leeds and his team analyzed normal, cirrhotic and cancerous (HCC) liver samples from patients over 10 years following a liver biopsy.

Bayer’s Stivarga Wins NICE Backing For Advanced Liver Cancer
29 November 2018
For patients who have taken sorafenib, there is a secondary treatment option called Stivarga (regorafenib). The National Institute for Health and Care Excellence (NICE) is recommending the usage of the new medication which is giving hope to patients. “Regorafenib for HCC offers the first licensed treatment option following failure on sorafenib which could significantly improve patient’s overall survival,” said Manjinder Bains, medical director Oncology, Bayer UK.

Sepsis Involved In 22% Of In-Hospital Deaths In Hepatocellular Carcinoma Patients
28 November 2018
A study was done on in-hospital patient deaths. Focusing on patients with HCC, researchers looked at 3,180 deaths between 2013 and 2017. they found that 713 of these deaths involved in severe sepsis. The percentage of HCC deaths that involve severe sepsis appears to exceed the percentage of overall cancer deaths that involve severe sepsis. HCC patients’ livers are extremely vulnerable to sepsis. Future sepsis treatments may include immunoadjuvant therapy.

Addressing Population Factors Contributing To Liver, Colon Cancers
19 November 2018
The Fourth Annual Liver Research Day was put in at The University of California at Davis; where the increased incidence of Hepatitis C in people between 50 and 70 as well as between 20 and 30. Risk factors in the development of HCC from Hep. C was discussed by Bradley Pollock as socioeconomic factors and social and medical histories. “Preventative healthcare calls for a specialized approach to research and to understanding cancer”.

Dr. Overman On The Combination Of Atezolizumab And Bevacizumab In HCC
16 November 2018
In July 2018, Tecentriq and Avastin were combined and allowed by the FDA to be considered a breakthrough therapy as a first line treatment for patients with resectable or advanced HCC. This therapy was used in a phase II clinical trial and presented at 2018 ESMO Congress to have high response rates. This is exciting news as a potential new combination therapy in the future for HCC patients.

New NCI-Funded Program Targets Early Detection Of Liver Cancer
14 November 2018
“The American Cancer Society estimates that there will be 42,000 new cases of primary liver cancer and 30,000 subsequent deaths in 2018 alone”. Clinical Research at The University of Michigan states that the reason why survival rates are so low for HCC is due to late detection of the disease. Molecular imaging is what is being introduced to potentially improve earlier HCC detection before the cancer progresses.

Osteopotin: A New Emerging Role In HCV-Related Hepatocellular Carcinoma
14 November 2018
Osteopotin is an immune cell that is involved in Hepatocellular Carcinoma and works with cancel stem cells. Therefore, continuing in research for the underlying mechanism of Hepatitis C pathogenesis and is relationship to cancer stem cells. There is a potential for new treatment options by targeting the role that Osteopotin plays with the stem cells that contribute to HCC.

Can-Fite Biopharma And Namodenoson In NAFLD/NASH: A Targeted Therapeutic Approach
13 November 2018
The clinical stage biopharma Can-Fite is focusing on a medication called Namodenoson that is targeted on chronic autoimmune, oncological and liver diseases with unmet needs. “Can-Fite proposes anti-inflammatory and anti-apoptotic responses for namodenoson in NAFLD/NASH and advanced Hepatocellular Carcinoma”.

DAAs Reduce HCC, Decompensation Risk Compared With No Treatment
12 November 2018
“Treatment outcomes showed that DAA therapy yielded a significant reduction in risk for developing HCC compared with no treatment (HR= 0.28; 95% Cl, 0.15-0.52) among patients with compensated cirrhosis”. Researchers at the University of Florida studied individuals with Hepatitis C who underwent DAA therapy and those who did not receive treatment. Significant reductions in HCC and decompensation risk were found in Cirrhotic patients who received DAA.

FDA OK’s Another PD-1 Inhibitor For HCC
9 November 2018
“Single-arm trial reported 17% response rate in sorafenib-treated patients”. Based on the results for the KEYNOTE-224 trial, the FDA has extended Keytruda to be used in patients with HCC. The medication Keytruda is to be used after patients use Nexavar as a first line treatment. This is exciting news for HCC patients, as the promising results indicate the treatment may bring relief. Keytruda is now the second PD-1 inhibitor approved for HCC following last year’s approval of Opdivo.

UCLA Awarded $3.5 Million To Develop Blood Test For Liver Cancer
7 November 2018
The National Institute of Health (NIH) granted UCLA to develop an affordable blood-based cancer screening test. Currently, at-risk patients are given ultrasounds to test for liver cancer detection. This blood test is going to be based on circulating tumor DNA in patients with cirrhosis of the liver. The research is being done at the UCLA Jonsson Comprehensive Cancer Center.

Liver Cancer Diagnosis Often Late Among African-American Patients
5 November 2018
Researchers at Stanford University Medical Center have found a difference in 5-year survival rates between African-American patients and Caucasian patients with HCC. “Long-term survival improved over time for Caucasians with HCC, but not for their African-American counterparts resulting in a survival difference between the two ethnic groups, though ethnicity was not a predictor of HCC mortality,” says Jacqueline Estevez, MD. A possible reason for this result is that African-American patients presented with more advanced stages of HCC than Caucasian patients.

Biomarkers To Detect And Prevent Liver Cancer
31 October 2018
In patients with precancerous cirrhotic livers, there may be a new identifier for researchers to help stop the development of liver cancer. By being able to pinpoint when the cirrhosis progresses to cancer, there would be an improvement in early detection and treatment for patients. The researchers are hopeful that this new marker may improve HCC survival.

Property Developer Accused Of Firing Employee Over Cancer
28 October 2018
A liver cancer patient who was fired from his job due to health discrimination. The patient wrote a complaint to the Human Rights Commission based on how he was let go from the company and not given his owed compensation because of his diagnosis of liver cancer. The company is a multi-billion dollar real estate developing company in Australia.

Utoledo Research Finds Link Between Refined Dietary Fiber, Gut Bacteria And Liver Cancer
18 October 2018
Through research at the University of Toledo, interesting results have been found regarding how processed dietary fibers may be inducing liver cancer. The way our gut bacteria breaks down this specific type of fiber is thus connected to the liver cancer risk. Dr. Vijay-Kumar says, “Our study is going against the conventional wisdom of what people think, that fiber is good, no matter how they get it. We do not want to promote that fiber is bas. Rather, we highlight that fortifying processed foods with refined soluble fiber may not be safe or advisable to certain individuals with gut bacterial overgrowth or dysbiosis, whose abnormal fermentation of this fiber could increase the susceptibility to liver cancer.”

Brewing Up A Healthy Lifestyle: Coffee And Body Fat Reduce Liver Cancer Risk
17 October 2018
“There is strong evidence that greater body fat, consumption of alcoholic drinks and eating foods contaminated with aflatoxins increase the risk of liver cancer,” according to AICR’s recently released Diet and Cancer Report. There is strong evidence that lifestyle factors play important roles in the possible increase risk of liver cancer. These factors are particular to what a person eats and drinks.

Low PNI Predicts Poor Liver Cancer Outcomes: Meta-Analysis Supports Prognostic Tool For Hepatocellular Carcinoma
16 October 2018
Researchers at Zhengzhou University in China created a meta-analysis of Asian studies on the ability for the prognostic nutritional index (PNI) to predict outcomes in HCC. Wang and his associates said ‘these pooled results suggested that high PNI is beneficial to the survival of HCC patients and associated with more favorable outcomes such as lower AFP, lower reoccurrence, minor tumor size, and better TNM’. It is important to note there were limitations with the study; however, the conclusion stands.

Liver Cancer Treatment Paradigm Undergoing Major Overhaul
15 October 2018
In the past few months, there has been a significant resurgence in the development of new HCC medications. For example, Lenvima was approved in August 2018 as a first-line treatment for patients with unresectable HCC as well as the accepted supplemental new drug application for Cabometryx in May of 2018. The expectation for patient survival is increasing with the positive results of clinical trials for these new medications, thus bringing new hope to patients.

Variable RBE Impacts Proton Therapy Of Liver Cancer
15 October 2018
Proton therapy offers the advantage of affecting less of the healthy liver tissues in HCC patients. “Radiation therapy for Hepatocellular Carcinoma is currently being investigated in several clinical trials, including proton therapy.” There is still too much uncertainty to readily use this therapy in patients, based on the variability that it has provided thus far.

Ongoing Trial Exploring Oncolytic Virus Pexa-Vec In HCC
8 October 2018
There is a phase 3 clinical trial that is comparing the use of Pexa-Vec and then Nexavar versus treatment with only Nexavar with the primary endpoint of the study being overall survival (OS). The researchers are currently recruiting for the PHOCUS trial and are looking for ‘600 patients with advanced HCC who have not received prior systemic therapy’.

Lower Liver Cancer Risk Seen With Tenotovir Treatment Of Chronic Hepatitis B
4 October 2018
“The risk of Hepatocellular Carcinoma (HCC) in patients with chronic hepatitis B (CHB) treated with tenofovir is lower than in those treated with entecavir, according to a nationwide study from South Korea.” The researchers mention that this information is only one observational study and more studies are needed.

Regular Aspirin Use Can Lower Risk For Ovarian, Liver Cancers
4 October 2018
Two studies from the Nurses’ Health Studies have shown a significant reduction of risk for HCC. The data was collected from nearly 90,000 women and nearly 46,000 men since the 1980s. “A regular dose of aspirin at least two or more times per week was associated with a 49 percent reduced risk of developing the disease. The observed benefit of aspirin was dose and duration dependent, appearing with aspirin use for five years or more, at a dose of 1.5 or more standard tablets per week.”

For HCV Patients, New Online Calculator Predicts HCC Risk After Treatment
3 October 2018
After using direct-acting antivirals (DAAs), patients with Hepatitis C may gain a response or no response. If there is a response, that information can be used in this new online calculator to assess the risk for HCC development in the future.

For past liver cancer news, please visit our Liver Cancer News Archives.

Scroll Up